Nonpeptide angiotensin II receptor antagonists.

@article{Timmermans1991NonpeptideAI,
  title={Nonpeptide angiotensin II receptor antagonists.},
  author={Pieter B.M.W.M. Timmermans and Pancras C Wong and Andrew T. Chiu and William F. Herblin},
  journal={Trends in pharmacological sciences},
  year={1991},
  volume={12 2},
  pages={
          55-62
        }
}
Substantial progress has been made recently in the development of nonpeptide angiotensin II receptor antagonists, a goal that has long remained an unmet challenge. Pieter Timmermans and colleagues review the pharmacology and the course of events that led to the identification of the lead compound and clinical candidate DuP753. Nonpeptide angiotensin II receptor antagonists represent novel therapeutic agents and are the preferred probes for exploring the (patho)physiological role(s) of… 
Angiotensin II receptor inhibition. A new therapeutic principle.
TLDR
It seems likely that the angiotensin receptor antagonists will be added to the list of drugs that have been deemed suitable for first-line therapy in the treatment of hypertension and congestive heart failure.
Medicinal Chemistry of Angiotensin II Antagonists
The renin—angiotensin system (RAS) has been demonstrated to be a key element in blood pressure regulation and sodium balance.1 The therapeutic and commercial success of angiotensin-converting enzyme
Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.
TLDR
A-II receptor antagonism appears to be as effective as ACE inhibition in the treatment of hypertension and other pathologic processes that involve the RAS and may offer an alternative to those patients who cannot tolerate ACE inhibitors because of their side effects.
Nonpeptide Angiotensin II Receptor Antagonists: Studies With EXP9270 and DuP 753
TLDR
The results suggest that Ang II receptors blockade is the primary mechanism of the antihypertensive effect of these nonpeptide Ang II receptor antagonists, and the specificity and lack of partial agonistic effects of these molecules make them potentially useful physiological probes and therapeutic agents.
Distinctions between non-peptide angiotensin II AT1-receptor antagonists
TLDR
A far-reaching understanding of the molecular action mechanism of AT1-receptor antagonists (AIIAs) was obtained by using CHO cells expressing transfected human AT 1-receptors, and it is concluded that all investigated antagonists are competitive with respect to Ang II.
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
TLDR
A series of low molecular weight nonpeptide imidazole analogues that possess weak but selective, competitive AT1 receptor blocking property are developed that cause a more complete RAAS blockade than ACE inhibitors.
Defining Angiotensin Receptor Subtypes
Historically, suggestions of multiple receptor subtypes for angiotensin II (ANG II) were based on a number of experimental observations involving the differences in the concentration—response
Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy
TLDR
Clinical studies confirm the AII antagonist action ofLosartan and suggest that losartan will be effective in the treatment of essential HTN, and the utility of AII antagonism may extend beyond that of HTN and CHF, as suggested by the potential usefulness of angiotensin‐converting enzyme inhibition.
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
TLDR
These drugs antagonize AII-induced biologic actions, including smooth-muscle contraction, sympathetic pressor mechanisms, and aldosterone release, and are the newest addition to the therapeutic armamentarium for the treatment of hypertensive diseases.
Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
This review surveys the basic pharmacology of angiotensin II receptors and their antagonism; reviews the existing clinical experience with losartan, the first approved nonpeptide angiotensin II
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Nonpeptide angiotensin II receptor antagonists.
TLDR
The nonpeptide structures described herein are selective and competitive AII receptor antagonists and add another dimension to the arsenal of drugs manipulating the RAS.
Antihypertensive mechanism of captopril in renal hypertensive rats: studies with a nonpeptide angiotensin II receptor antagonist and an angiotensin II monoclonal antibody.
TLDR
Results suggest that the antihypertensive effect of captopril in conscious RALRs is due mainly to the blockade of AII formation, and circulating AII rather than locally formed AII appears to play a major role in maintaining hypertension in hypertension in RALRS.
Nonpeptide Angiotensin II Receptor Antagonists. IV. EXP6155 and EXP6803
TLDR
The results indicate that EXP6155 and EXP6803 are selective angiotensin II receptor antagonists and antihypertensive agents, and may represent preferred probes for studying the physiological roles of angiotENSin II.
Inhibition of induced aldosterone biosynthesis with a specific antagonist of angiotensin II.
  • A. Chiu, M. Peach
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1974
TLDR
The data suggest that des-Asp(1)-angiotensin II has a much higher affinity for the angiotENSin receptor in adrenal cortex than angiotens in II, and may be responsible for steroidogenesis and induced aldosterone synthesis.
Actions of angiotensin II on the brain: mechanisms and physiologic role.
  • I. Reid
  • Biology, Medicine
    The American journal of physiology
  • 1984
TLDR
Much additional research will be required before the actions of angiotensin II on the brain are completely understood, and the physiologic significance of these actions is beginning to be understood.
Organ specificity of angiotensin II and Des-aspartyl angiotensin II in the conscious rat.
TLDR
A high degree of organ specificity or selectivity for des-Asp AII and a low specificity for AII is illustrated and may thus be formed from AII locally in the adrenal gland prior to exerting its action at that site.
Functions of Angiotensin in the Central Nervous System
TLDR
It is suggested that normally, a blood-CVO barrier prevents diffusion of peripheral Ang II to brain receptors inside the BBB, and when systemic peptide levels are low, Ang II activates only receptors in the CVOs; however, when these levels are high, the peptide diffuses to receptors that are normally activated only by brain Ang II.
Formation of angiotensin III by angiotensin-converting enzyme.
TLDR
As suggested by the Km values, bradykinin, peptide BPP9a and angiotensins II and III are better inhibitors of the formation ofAngiotensin II than of theformation of ang Elliotensin III.
Effect of an angiotensin converting enzyme inhibitor (SQ 14,225) on beta-adrenergic and angiotensin-induced thirsts.
TLDR
The results suggest that isoprenaline-induced thirst is mediated by way of the renin--angiotensin system.
pA, a new scale for the measurement of drug antagonism.
  • H. Schild
  • Chemistry, Medicine
    British journal of pharmacology and chemotherapy
  • 1947
TLDR
This is the first of a set of three papers in the Journal that were to transform the study of drug antagonism and Schild proposed and validated a new measure of antagonist action, pA, and showed how pAx measurements could provide a reproducible and statistically satisfactory index of the effectiveness of an antagonist action.
...
1
2
...